GlassScriptPhysician profile
Donald G Nicholas
NPI 1245226950
$1,890.90
in general payments reported to CMS, 2019-2025
25 companies · $259 in 2025
The $259 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $730 · 2020: $272 · 2022: $413 · 2024: $217 · 2025: $259.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $476.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $476.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $350.08 | 2019-2025 | Ozempic |
| Amarin Pharma, INC. | $224.33 | 2019-2020 | |
| Abbott Laboratories | $189.69 | 2022-2024 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $131.99 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.48 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $92.46 | 2019-2022 | |
| Amgen INC. | $76.84 | 2019-2024 | Krystexxa |
| Arbor Pharmaceuticals, INC. | $75.65 | 2019-2020 | |
| Exact Sciences Corporation | $60.24 | 2025 | The Cologuard Plus Collection Kit |
| Kowa Pharmaceuticals America, INC. | $60.12 | 2019-2022 | |
| Pfizer INC. | $58.57 | 2019 | |
| Allergan, INC. | $57.57 | 2019 | |
| Lilly USA, LLC | $55.47 | 2022-2025 | Jardiance, Mounjaro, Zepbound |
| Novartis Pharmaceuticals Corporation | $50.57 | 2022 | |
| Sanofi-Aventis U.S. LLC | $45.42 | 2019-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.75 | 2019 | |
| Edwards Lifesciences Corporation | $40.14 | 2022 | |
| Abbvie INC. | $35.68 | 2022 | |
| Supernus Pharmaceuticals, INC. | $27.84 | 2019 | |
| Merck Sharp & Dohme LLC | $22.14 | 2019 | |
| Shield Therapeutics INC | $21.85 | 2024 | |
| Dexcom, INC. | $19.04 | 2025 | Dexcom G6 Transmitter |
| Daiichi Sankyo INC. | $16.24 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $14.99 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Nicholas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.